Inozyme Pharma, Inc.
NasdaqGS:INZY Voorraadrapport
Marktkapitalisatie: US$257.0m
Inozyme Pharma Toekomstige groei
Future criteriumcontroles 0/6 De winst van Inozyme Pharma zal naar verwachting dalen met 0.5% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 82.6% per jaar. De winst per aandeel zal naar verwachting groeien met 18.1% per jaar.
Belangrijke informatie
18.1%
Groei van de winst per aandeel
Biotechs winstgroei 27.3% Inkomstengroei 82.6% Toekomstig rendement op eigen vermogen n/a Dekking van analisten Good
Laatst bijgewerkt 07 Nov 2024
Recente toekomstige groei-updates
Price target decreased by 7.5% to US$19.43 May 31
Price target decreased by 9.3% to US$20.50 Aug 06
Price target increased by 8.5% to US$22.60 Jul 28
Price target decreased by 13% to US$19.17 Mar 29
Price target increased by 8.5% to US$21.80 Feb 15
Price target increased to US$23.20 Aug 17
Toon alle updates
New major risk - Revenue and earnings growth Nov 10
New major risk - Revenue and earnings growth Nov 06
Inozyme Pharma, Inc. Announces Positive Interim Data from Phase 1 Seaport 1 Trial of INZ-701 Oct 25
Inozyme Pharma, Inc. Announces Appointment of Erik Harris to its Board of Directors Oct 07
New major risk - Financial position Aug 07
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? Aug 03
Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion Jul 30
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency Jul 02
New major risk - Revenue and earnings growth Jun 11
Price target decreased by 7.5% to US$19.43 May 31
New major risk - Revenue and earnings growth May 07
Inozyme Pharma, Inc., Annual General Meeting, Jun 18, 2024 Apr 28
Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry? Apr 11
Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency (PXE) and ENPP1 Deficiency Apr 10
CEO & Chairman exercised options and sold US$52k worth of stock Apr 05
New minor risk - Share price stability Mar 28
Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency Mar 27
New major risk - Revenue and earnings growth Mar 12
Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward Mar 08
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions Oct 11
Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) Sep 27
New minor risk - Share price stability Aug 07
Price target decreased by 9.3% to US$20.50 Aug 06
New major risk - Shareholder dilution Aug 04
New major risk - Revenue and earnings growth Aug 03 Inozyme Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $60 million. Jul 29
Price target increased by 8.5% to US$22.60 Jul 28
Inozyme Pharma, Inc. Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency Jul 27
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in Phase 1b Trial of INZ-701 Jun 28
Insufficient new directors Jun 02
Price target decreased by 13% to US$19.17 Mar 29
Inozyme Pharma, Inc. Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 Feb 17
Price target increased by 8.5% to US$21.80 Feb 15 Inozyme Pharma, Inc. Provides Business Updates
Inozyme Pharma, Inc. Announces First Self-Administration of Inz-701 in Ongoing Enpp1 Deficiency Phase 1/2 Clinical Trial Nov 04
Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database Nov 01
Price target increased to US$23.20 Aug 17
Inozyme Pharma GAAP EPS of -$0.38 Aug 15
Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE) Jul 20
Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency Jul 19
Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely? Jul 12
Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Index Jun 26
Inozyme Pharma, Inc. Appoints Kurt Gunter as Chief Medical Officer Jun 08
Price target decreased to US$29.40 Apr 27
Inozyme Pharma, Inc. Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency Apr 13
We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate Apr 06
Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency Apr 05
Price target decreased to US$30.00 Mar 18 Inozyme Pharma, Inc. Announces Management Changes
High number of new directors Dec 31
Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation Dec 22
Price target decreased to US$32.25 Nov 30
Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth Sep 08
Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency Jul 23 Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Growth Index
President exercised options and sold US$65k worth of stock Jun 26
Inozyme Pharma, Inc. Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of Inz-701 in Abcc6 Deficiency Jun 10
We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate May 22
Senior Vice President of Finance Stephen Basso has left the company May 16
Inozyme Pharma, Inc. Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency May 08
Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency May 07
Member of Scientific Advisory Board has left the company Apr 02
Member of Scientific Advisory Board has left the company Apr 02
Member of Scientific Advisory Board has left the company Apr 02
New 90-day low: US$19.96 Feb 12
We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely Feb 06
Inozyme Pharma Announces Executive Changes Feb 05
Senior VP & Chief Medical Officer has left the company Feb 05
New 90-day high: US$27.90 Jan 16
Inozyme Pharma, Inc. Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency Jan 05
Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder Jan 04
Inozyme Pharma (INZY) Investor Presentation - Slideshow Dec 03
Inozyme Pharma EPS misses by $1.02 Nov 12
Inozyme Pharma Appoints Kevin B. Johnson as Senior Vice President, Regulatory Affairs Nov 10
Inozyme Pharma, Inc. Announces Executive Changes Oct 14
Inozyme Pharma, Inc. has completed an IPO in the amount of $112 million. Jul 24
Winst- en omzetgroeiprognoses NasdaqGS:INZY - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions ) Datum Inkomsten Inkomsten Vrije kasstroom Geldmiddelen uit operationele activiteiten Gem. Aantal analisten 12/31/2026 8 -151 -157 -143 8 12/31/2025 N/A -127 -126 -125 8 12/31/2024 N/A -102 -93 -97 8 9/30/2024 N/A -96 -91 -91 N/A 6/30/2024 N/A -89 -86 -86 N/A 3/31/2024 N/A -77 -78 -77 N/A 12/31/2023 N/A -71 -71 -71 N/A 9/30/2023 N/A -68 -67 -67 N/A 6/30/2023 N/A -68 -63 -62 N/A 3/31/2023 N/A -68 -62 -61 N/A 12/31/2022 N/A -67 -58 -58 N/A 9/30/2022 N/A -67 -57 -57 N/A 6/30/2022 N/A -65 -55 -55 N/A 3/31/2022 N/A -62 -50 -50 N/A 12/31/2021 N/A -57 -49 -48 N/A 9/30/2021 N/A -49 -46 -46 N/A 6/30/2021 N/A -63 -44 -43 N/A 3/31/2021 N/A -60 -43 -42 N/A 12/31/2020 N/A -56 -37 -36 N/A 9/30/2020 N/A -52 -31 -30 N/A 6/30/2020 N/A -28 -24 -24 N/A 3/31/2020 N/A -22 -20 -20 N/A 12/31/2019 N/A -20 -19 -19 N/A
Meer tonen
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat INZY de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat INZY de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat INZY de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: Er wordt verwacht dat INZY volgend jaar geen omzet zal hebben.
Hoge groei-inkomsten: Er wordt verwacht dat INZY volgend jaar geen omzet zal hebben.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van INZY naar verwachting over 3 jaar hoog zal zijn
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
